Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Precisis
Heidelberg, Baden-Württemberg, Germany
- Ownership
- Private
- Development stage
- Other
01
Overview
EASEE, a CE‑marked epicranial neuromodulation implant for drug‑resistant focal epilepsy, has been commercially available in Europe since 2023 with encouraging real‑world clinical experience; in the U.S., a pivotal IDE‑approved, randomized, double‑blind, sham‑controlled EASEE4US trial is starting to support future FDA premarket approval.[2][3]
- Therapeutic areas
- PsychiatryNeurology
- Modalities
- DeviceNon-pharmacological therapy
- Industry
- Implantable Medical Devices
02
Partnerships
AION Biotech (Italian commercialization partner for EASEE)[5]European Investment Bank (venture loan financing partner)[3]
Beyond the preview
Go deeper on Precisis.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Precisis.